Countries
Institutions
Fields
Rankings
Compare

Search institutions, scholars, countries and publications

Sankore

Named after the University of Sankore in Timbuktu — one of the world’s oldest centres of learning. Every figure here is computed from work-level records in our own graph, never copied from a source’s summary count.

Built from

OpenAlex — works, authorships, subject classification
ROR — institutional identity
ORCID — researcher identity
Crossref — publisher confirmation

Browse

Countries
Institutions
Fields
Rankings
What we cover

Coverage is partial and says so. A country appears with its research output only once its works have been swept; until then the portal shows whatever the graph happens to hold for it and labels it as exactly that.

Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9–14 years of age: Interim analysis from a phase 3 clinical trial

2024VaccineJournalOpen access

10.1016/j.vaccine.2024.02.077 Full text23 citations

Authors

13 authors across 5 institutions in 3 countries.

K. ZamanFirst author
as printed: Khalequ Zaman
Anne E SchuindCorresponding
Samuel Adjei
- Kwame Nkrumah University of Science and Technology (GH)
- Presbyterian University, Ghana (GH)
Kalpana Antony
John Aponte
as printed: John J Aponte
Patrick BY Buabeng
- Kwame Nkrumah University of Science and Technology (GH)
- Presbyterian University, Ghana (GH)
Firdausi Qadri
Troy J Kemp
Lokman Hossain
Ligia A Pinto
Kristen Sukraw
Niranjan Bhat
Tsiri AgbenyegaSenior author
- Kwame Nkrumah University of Science and Technology (GH)
- Presbyterian University, Ghana (GH)

Fields

Assignment is probabilistic — a work belongs to several fields in proportions.

Cervical Cancer and HPV Researchlevel 3 · 0.71
Biological Research and Disease Studieslevel 3 · 0.09
Herpesvirus Infections and Treatmentslevel 3 · 0.04

Sources

Several sources describing one work is the point — it means the record rests on more than one authority.

openalexseen September 5, 2026
2024 · Vaccine · 23 citations
https://openalex.org/W4392357500

Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9–14 years of age: Interim analysis from a phase 3 clinical trial · Sankore